Cord Blood Banking Leader Cryo-Cell Announces Regular Quarterly Cash Dividend and Pause of Strategic Initiatives
Cryo-Cell International (NYSE American: CCEL), the world's first private cord blood bank, has announced two significant developments. First, the company's Board of Directors has approved a quarterly cash dividend of $0.25 per share of common stock, payable on February 28, 2025, to shareholders of record as of February 14, 2025. Second, the company has paused its strategic initiatives related to potential sale or merger activities.
The Board will continue to evaluate the dividend policy regularly, though they note there is no guarantee of future dividend payments. Cryo-Cell, which pioneered stem cell separation and storage in 1992, maintains its position as a leader in cord blood banking.
Cryo-Cell International (NYSE American: CCEL), il primo banco privato di sangue cordonale al mondo, ha annunciato due sviluppi significativi. In primo luogo, il Consiglio di Amministrazione dell'azienda ha approvato un dividendo in contante trimestrale di $0,25 per azione di azioni ordinarie, che sarà pagato il 28 febbraio 2025, agli azionisti registrati al 14 febbraio 2025. In secondo luogo, l'azienda ha sospeso le proprie iniziative strategiche relative a potenziali vendite o attività di fusione.
Il Consiglio continuerà a valutare regolarmente la politica dei dividendi, anche se nota che non c'è garanzia di pagamenti futuri. Cryo-Cell, che ha pionierato la separazione e la conservazione delle cellule staminali nel 1992, mantiene la sua posizione di leader nel settore del banking del sangue cordonale.
Cryo-Cell International (NYSE American: CCEL), el primer banco privado de sangre de cordón umbilical en el mundo, ha anunciado dos desarrollos significativos. En primer lugar, la Junta Directiva de la empresa ha aprobado un dividendo en efectivo trimestral de $0.25 por acción de acciones comunes, que se pagará el 28 de febrero de 2025, a los accionistas registrados hasta el 14 de febrero de 2025. En segundo lugar, la empresa ha detenido sus iniciativas estratégicas relacionadas con posibles actividades de venta o fusión.
La Junta seguirá evaluando la política de dividendos regularmente, aunque señala que no hay garantía de pagos de dividendos futuros. Cryo-Cell, que pionera en la separación y almacenamiento de células madre en 1992, mantiene su posición como líder en el banco de sangre de cordón.
Cryo-Cell International (NYSE American: CCEL), 세계 최초의 민간 제대혈 은행, 두 가지 중요한 개발 사항을 발표했습니다. 첫째, 회사 이사회는 주당 $0.25의 분기 현금 배당금을 승인하였으며, 2025년 2월 28일에 2025년 2월 14일 기준 주주에게 지급될 예정입니다. 둘째, 회사는 잠재적인 매각 또는 합병 활동과 관련된 전략적 이니셔티브를 중단했습니다.
이사회는 정기적으로 배당 정책을 평가할 예정이지만, 앞으로의 배당금 지급에 대한 보장은 없다고 언급했습니다. 1992년 줄기세포 분리 및 저장에서 선구적인 역할을 한 Cryo-Cell은 제대혈 은행 부문에서 선두 자리를 유지하고 있습니다.
Cryo-Cell International (NYSE American: CCEL), la première banque privée de sang de cordon au monde, a annoncé deux développements importants. Premièrement, le Conseil d'Administration de la société a approuvé un dividende en espèces trimestriel de 0,25 $ par action d'actions ordinaires, payable le 28 février 2025, aux actionnaires inscrits au 14 février 2025. Deuxièmement, la société a mis en pause ses initiatives stratégiques liées à des ventes ou des fusions potentielles.
Le Conseil continuera d'évaluer régulièrement la politique de dividendes, bien qu'il soit noté qu'il n'y a aucune garantie de paiements de dividendes futurs. Cryo-Cell, qui a été pionnière dans la séparation et le stockage des cellules souches en 1992, maintient sa position de leader dans le domaine de la banque de sang de cordon.
Cryo-Cell International (NYSE American: CCEL), die weltweit erste private Nabelschnurblutbank, hat zwei bedeutende Entwicklungen bekannt gegeben. Erstens hat der Vorstand des Unternehmens eine Vorschlagsrate von $0,25 pro Aktie für Stammaktien genehmigt, die am 28. Februar 2025 an Aktionäre, die am 14. Februar 2025 im Handel sind, ausgezahlt wird. Zweitens hat das Unternehmen seine strategischen Initiativen gestoppt, die sich auf potenzielle Verkaufs- oder Fusionsaktivitäten beziehen.
Der Vorstand wird die Dividendenpolitik regelmäßig bewerten, bemerkt jedoch, dass es keine Garantie für zukünftige Dividendenzahlungen gibt. Cryo-Cell, das 1992 Pionierarbeit in der Trennung und Lagerung von Stammzellen geleistet hat, behauptet weiterhin seine Position als Marktführer im Bereich Nabelschnurblutbanking.
- Quarterly dividend of $0.25 per share announced
- Company maintains consistent dividend payment schedule
- Suspension of strategic initiatives regarding potential sale or merger
- No assurance of future dividend payments
The Company also announced that it has paused its strategic initiatives relating to the possible sale or merger of the Company.
About Cryo-Cell International, Inc.
Founded in 1989, Cryo-Cell International, Inc. is the world’s first private cord blood bank. More than 500,000 parents from 87 countries have entrusted Cryo-Cell International with their baby’s cord blood and cord tissue stem cells. In addition to its private bank, Cryo-Cell International has a public banking program in partnership with Duke University. Cryo-Cell’s public bank has provided cord blood for more than 600 transplantations and operates cord blood donation sites across the
Cryo-Cell’s mission is to provide the premier cord blood and cord tissue cryopreservation services, to develop, manufacture and administer cellular therapies to significantly improve the lives of patients worldwide and to offer the highest quality and most cost effective biostorage solutions available.
Forward-Looking Statements
This press release includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). In some cases, you can identify forward-looking statements by terminology such as “will,” “may,” “should,” “could,” “would,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “forecasts,” “potential” or “continue” or the negative of these terms or other comparable terminology. Generally, the words “anticipate,” “believe,” “continue,” “expect,” “intend,” “estimate,” “project,” “plan” and similar expressions identify forward-looking statements. In particular, statements about our expectations, beliefs, plans, objectives, assumptions or future events or performance contain forward-looking statements.
We have based these forward-looking statements on our current expectations, assumptions, estimates and projections. These forward-looking statements involve risks and uncertainties and reflect only our current views, expectations and assumptions with respect to future events and our future performance. If risks or uncertainties materialize or assumptions prove incorrect, actual results or events could differ materially from those expressed or implied by such forward-looking statements. Risks that could cause actual results to differ from those expressed or implied by the forward-looking statements we make include, among others, the success of the Company’s global expansion initiatives and product diversification, including its addition of the ExtraVault services, the Company’s actual future ownership stake in future therapies emerging from its collaborative research partnerships, the success related to its IP portfolio, the Company’s future competitive position in stem cell innovation, future success of its core business and the competitive impact of public cord blood banking on the Company’s business, the success of the Company’s initiative to expand its core business units to include biopharmaceutical manufacturing and operating clinics, the complexities, uncertainties, required consents and timing related to the potential spinoff of Celle Corp., the uncertainty of profitability from its biopharmaceutical manufacturing and operating clinics, the Company’s ability to minimize future costs to the Company related to R&D initiatives and collaborations and the success of such initiatives and collaborations and the success and enforceability of the Company’s umbilical cord blood and cord tissue license agreements, together with the associated intellectual property and their ability to provide the Company with royalty fees, along with the Risk Factors set forth in the Company’s Form 10-Q filed on October 15, 2024.
This list of risks and uncertainties, however, is only a summary of some of the most important factors and is not intended to be exhaustive. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements. These risks and uncertainties may cause our actual future results to be materially different than those expressed in our forward-looking statements. These forward-looking statements are made only as of the date hereof. Except as otherwise required by applicable law, we do not undertake and expressly disclaim any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments. All subsequent written and oral forward-looking statements attributable to us, or to persons acting on our behalf, are expressly qualified in their entirety by these cautionary statements.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250129041390/en/
Irene Smith
813-749-2102
Ismith@cryo-cell.com
Source: Cryo-Cell International, Inc.
FAQ
When will Cryo-Cell (CCEL) pay its next dividend?
What is the dividend amount for CCEL stock?
Why has Cryo-Cell (CCEL) paused its strategic initiatives?
What is the ex-dividend date for CCEL's February 2025 dividend?
